Search research articles
Contact Us
Filters
Showing results (121-130 of 162) with videos related to
Page
of 17
Sort By:
Nature Communications
|
November 8, 2018
Epigenetic profiling for the molecular classification of metastatic brain tumors
Javier I J Orozco, Theo A Knijnenburg, Ayla O Manughian-Peter, et al.
The Lancet. Oncology
|
June 8, 2019
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF<sup>V600</sup> mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial
Georgina V Long, Robyn P M Saw, Serigne Lo, et al.
Histopathology
|
November 21, 2015
Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome
Rhiannon K Beckers, Christina I Selinger, Ricardo Vilain, et al.
Nature Cancer
|
February 5, 2022
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma
Lisa Haas, Anais Elewaut, Camille L Gerard, et al.
Oncoimmunology
|
February 5, 2019
Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients
Hansol Lee, Camelia Quek, Ines Silva, et al.
Nucleic Acids Research
|
May 3, 2018
Telomere sequence content can be used to determine ALT activity in tumours
Michael Lee, Erdahl T Teber, Oliver Holmes, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
April 16, 2025
Longitudinal Analysis Reveals Dynamic Changes in Histopathologic Features in Responders to Neoadjuvant Treatment in a Stage III BRAF-Mutant Melanoma Cohort
Jorja Braden, Alison Potter, Robert V Rawson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 15, 2023
Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Hansol Lee, Angela L Ferguson, Camelia Quek, et al.
Nature Communications
|
February 28, 2013
PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma
Yan Ye, Lei Jin, James S Wilmott, et al.
Cell Reports
|
June 30, 2024
Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy
Camelia Quek, Aditya Pratapa, Xinyu Bai, et al.
Page
of 17
Search research articles
Search
Showing results (121-130 of 162) with videos related to
Sort By:
Page
of 17
Nature Communications
|
November 8, 2018
Epigenetic profiling for the molecular classification of metastatic brain tumors
Javier I J Orozco, Theo A Knijnenburg, Ayla O Manughian-Peter, et al.
The Lancet. Oncology
|
June 8, 2019
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF<sup>V600</sup> mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial
Georgina V Long, Robyn P M Saw, Serigne Lo, et al.
Histopathology
|
November 21, 2015
Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome
Rhiannon K Beckers, Christina I Selinger, Ricardo Vilain, et al.
Nature Cancer
|
February 5, 2022
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma
Lisa Haas, Anais Elewaut, Camille L Gerard, et al.
Oncoimmunology
|
February 5, 2019
Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients
Hansol Lee, Camelia Quek, Ines Silva, et al.
Nucleic Acids Research
|
May 3, 2018
Telomere sequence content can be used to determine ALT activity in tumours
Michael Lee, Erdahl T Teber, Oliver Holmes, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
April 16, 2025
Longitudinal Analysis Reveals Dynamic Changes in Histopathologic Features in Responders to Neoadjuvant Treatment in a Stage III BRAF-Mutant Melanoma Cohort
Jorja Braden, Alison Potter, Robert V Rawson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 15, 2023
Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Hansol Lee, Angela L Ferguson, Camelia Quek, et al.
Nature Communications
|
February 28, 2013
PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma
Yan Ye, Lei Jin, James S Wilmott, et al.
Cell Reports
|
June 30, 2024
Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy
Camelia Quek, Aditya Pratapa, Xinyu Bai, et al.
Page
of 17